Glutamate decarboxylase (GAD65) and tyrosine phosphatase-like protein (IA-2) autoantibodies index in a regional population is related to glucose intolerance and body mass index

被引:59
作者
Rolandsson, O
Hägg, E
Hampe, C
Sullivan, EP
Nilsson, M
Jansson, G
Hallmans, G
Lernmark, Å
机构
[1] Umea Univ, Dept Family Med, S-90185 Umea, Sweden
[2] Umea Univ, Dept Med, S-90185 Umea, Sweden
[3] Univ Washington, Dept Med, Seattle, WA 98195 USA
[4] Umea Univ, Dept Epidemiol, S-90185 Umea, Sweden
[5] Stenbergska Primary Hlth Care Ctr, Lycksele, Sweden
[6] Umea Univ, Dept Nutr Res, S-90185 Umea, Sweden
关键词
autoimmunity; beta-cell function; BMI; epidemiology; sex; glutamate decarboxylase; IA-2; Type I and type II diabetes; OGTT;
D O I
10.1007/s001250051194
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aims/hypothesis. Our aims were to investigate the concentrations and prevalence of autoantibodies against the Mr 65.000 isoform of glutamate decarboxylase (GAD65) and the tyrosine phosphatase-like protein (IA-2) in adults and to test the hypothesis that GAD65 and IA-2 autoantibodies in a regional population are related to abnormal oral glucose tolerance. Methods. We analysed serum from 2157 Swedish subjects aged either 30, 40, 50 or 60 years old who, in 1988-1992, participated in the Vasterbotten County Health Project and were subjected to the World Health Organisation (WHO) standard oral glucose tolerance test at entry into the study. Results. We found 23 of 2157 (1.1%) and 17 of 2152 (0.8%) subjects exceeded the 99th centile of GAD65 autoantibody index and IA-2 autoantibody index, respectively. In 18 subjects with diabetic oral glucose tolerance test, GAD65 autoantibody concentrations were higher than in those with normal oral glucose tolerance test (p = 0.02). Subjects with IGT (n = 416) and diabetes (n = 18), i. e. abnormal OGTT (n = 434), had a higher IA-2Ab index compared with those with normal OGTT (p = 0.008). A stepwise multiple logistic regression test showed that the odds ratios for subjects in the highest BMI group to exceed the 95th or 99th GAD65 autoantibody centile were 3.6 (CI 1.4-8.9) and 17.6 (CI 2.6-121.6), respectively. Conclusion/interpretation. GAD65 and IA-2 autoantibodies, are associated with impaired or diabetic glucose tolerance in an adult regional population. This observation together with the association between GAD65 autoantibody concentrations and body mass index indicate a possible relation between islet autoimmunity and beta-cell function abnormalities with obesity and insulin resistance.
引用
收藏
页码:555 / 559
页数:5
相关论文
共 19 条
[1]   EXPRESSION OF THE 64 KDA/GLUTAMIC ACID DECARBOXYLASE RAT ISLET CELL AUTOANTIGEN IS INFLUENCED BY THE RATE OF INSULIN-SECRETION [J].
BJORK, E ;
KAMPE, O ;
ANDERSSON, A ;
KARLSSON, FA .
DIABETOLOGIA, 1992, 35 (05) :490-493
[2]   RADIOIMMUNOASSAYS FOR GLUTAMIC-ACID DECARBOXYLASE (GAD65) AND GAD65 AUTOANTIBODIES USING S-35 OR H-3 RECOMBINANT HUMAN LIGANDS [J].
FALORNI, A ;
ORTQVIST, E ;
PERSSON, B ;
LERNMARK, A .
JOURNAL OF IMMUNOLOGICAL METHODS, 1995, 186 (01) :89-99
[3]  
Fukui M, 1997, DIABETIC MED, V14, P148
[4]   GLUTAMATE-DECARBOXYLASE ANTIBODY-LEVELS PREDICT RATE OF BETA-CELL DECLINE IN ADULT-ONSET DIABETES [J].
GOTTSATER, A ;
LANDINOLSSON, M ;
LERNMARK, A ;
FERNLUND, P ;
SUNDKVIST, G ;
HAGOPIAN, WA .
DIABETES RESEARCH AND CLINICAL PRACTICE, 1995, 27 (02) :133-140
[5]  
GRUBIN CE, 1994, DIABETOLOGIA, V37, P344, DOI 10.1007/BF00408469
[6]   QUANTITATIVE ASSAY USING RECOMBINANT HUMAN ISLET GLUTAMIC-ACID DECARBOXYLASE (GAD65) SHOWS THAT 64K AUTOANTIBODY POSITIVITY AT ONSET PREDICTS DIABETES TYPE [J].
HAGOPIAN, WA ;
KARLSEN, AE ;
GOTTSATER, A ;
LANDINOLSSON, M ;
GRUBIN, CE ;
SUNDKVIST, G ;
PETERSEN, JS ;
BOEL, E ;
DYRBERG, T ;
LERNMARK, A .
JOURNAL OF CLINICAL INVESTIGATION, 1993, 91 (01) :368-374
[7]   GLUTAMATE DECARBOXYLASE-ANTIBODIES, INSULIN-ANTIBODIES AND ISLET-CELL-ANTIBODIES AND HLA TYPING TO DETECT DIABETES IN A GENERAL POPULATION-BASED STUDY OF SWEDISH CHILDREN [J].
HAGOPIAN, WA ;
SANJEEVI, CB ;
KOCKUM, I ;
LANDINOLSSON, M ;
KARLSEN, AE ;
SUNDKVIST, G ;
DAHLQUIST, G ;
PALMER, J ;
LERNMARK, A .
JOURNAL OF CLINICAL INVESTIGATION, 1995, 95 (04) :1505-1511
[8]  
IRVINE WJ, 1979, J CLIN LAB IMMUNOL, V2, P23
[9]   Small doses of subcutaneous insulin as a strategy for preventing slowly progressive beta-cell failure in islet cell antibody-positive patients with clinical features of NIDDM [J].
Kobayashi, T ;
Nakanishi, K ;
Murase, T ;
Kosaka, K .
DIABETES, 1996, 45 (05) :622-626
[10]   GAD ANTIBODIES IN NIDDM - 10-YEAR FOLLOW-UP FROM THE DIAGNOSIS [J].
NISKANEN, LK ;
TUOMI, T ;
KARJALAINEN, J ;
GROOP, LC ;
UUSITUPA, MIJ .
DIABETES CARE, 1995, 18 (12) :1557-1565